NextCure, Inc.
NXTCNextCure, Inc. in brief
NextCure, Inc. is a listed company in the Biotechnology industry, based in Baltimore, Maryland, USA. Its market value was $30 M on 30 October 2026, which makes it the 23,092nd largest listed company in the world and the 4,046th largest in the USA on this site. Michael Richman is its chief executive. Its shares trade under the symbol NXTC (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About NextCure, Inc.
NextCure is a Clinical Stage Biopharmaceutical company. It is committed to discovering and developing novel, first in class immunomedicines to treat cancer and other immune related diseases by restoring normal immune function. It provides a large repertoire of function based screens and imparts a unique understanding of cell surface molecular interactions between immune and diseased cells. The headquarters is in USA.
NextCure, Inc. timeline
- 2016
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2019
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 9 May 2019; shares registered for exchange trading on 8 May 2019.
Events of NextCure, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,817 (Jan 2020) · #2,954 (Jan 2021) · #4,056 (Jan 2022) · #5,023 (Dec 2022) · #4,781 (Jul 2023) · #4,232 (Jan 2024) · #2,075 (Mar 2026) · #3,809 (Aug 2026) · #4,029 (Oct 2026) · #4,049 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.9×
- Free cash flow yield
- -138.0%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -159.8%
- Liabilities / assets
- 30.4%
- Net debt
- $-27M
- Revenue growth
- +252.4%
- R&D / revenue
- 208.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-58M | $-56M | — |
| Dec 2024 | — | — | $-60M | $-56M | — |
| Dec 2023 | — | — | $-68M | $-63M | — |
| Dec 2022 | — | — | $-76M | $-75M | — |
| Dec 2021 | — | — | $-71M | $-69M | — |
| Dec 2020 | $22M | +252.4% | $-41M | $-37M | -163.5% |
| Dec 2019 | $6M | — | $-37M | $-34M | -531.3% |
| Dec 2018 | — | — | $-23M | $-23M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-50M | — | — | $-19.65 | $0.00 |
| Dec 2024 | $-41M | $0M | $-41M | $-23.88 | $0.00 |
| Dec 2023 | $-53M | $1M | $-54M | $-2.25 | $0.00 |
| Dec 2022 | $-54M | $2M | $-56M | $-2.69 | $0.00 |
| Dec 2021 | $-57M | $2M | $-60M | $-2.51 | $0.00 |
| Dec 2020 | $-45M | $7M | $-52M | $-1.33 | $0.00 |
| Dec 2019 | $-36M | $3M | $-39M | $-2.15 | $0.00 |
| Dec 2018 | $8M | $3M | $5M | $-16.64 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Oct 30, 20268-KCurrent reportDirectors or officers changed
- Sep 25, 20268-KCurrent reportOther events
- Sep 3, 20268-KCurrent reportMaterial agreement
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jul 14, 20268-KCurrent reportMaterial agreement · Restructuring costs · Change in control · Directors or officers changed · Regulation FD disclosure · Other events
- Jun 25, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Jun 1, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 7, 202610-QQuarterly report · period to Mar 2026
- May 7, 20268-KCurrent reportResults of operations
Official filings of NextCure, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-58 M
- Net income
- $-56 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $50 M
- Total liabilities
- $15 M
- Total equity
- $35 M
As of December-2025
Top 33 institutional investors in NextCure, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | ADAR1 Capital Management, LLC | 722,419 | New | 15.78% | $4 M | Nov 16, 2026 |
| 2 | Adage Capital Partners GP, L.L.C. | 377,202 | +100,000 (+36.07%) | 8.24% | $2 M | Nov 16, 2026 |
| 3 | Affinity Asset Advisors, LLC | 291,960 | +250,000 (+595.81%) | 6.38% | $1 M | Nov 13, 2026 |
| 4 | Blackstone Inc. | 224,000 | New | 4.89% | $1 M | Nov 16, 2026 |
| 5 | Sofinnova Investments, Inc. | 222,654 | 0 (0.00%) | 4.86% | $1 M | Nov 16, 2026 |
| 6 | Eversept Partners, LP | 185,455 | New | 4.05% | $1 M | Nov 16, 2026 |
| 7 | Vanguard Capital Management LLC | 156,842 | 0 (0.00%) | 3.43% | $1 M | Nov 13, 2026 |
| 8 | Citadel Advisors LLC | 110,660 | New | 2.42% | $1 M | Nov 16, 2026 |
| 9 | Verition Fund Management LLC | 92,946 | New | 2.03% | $0 M | Nov 13, 2026 |
| 10 | Soleus Capital Management, L.P. | 90,000 | New | 1.97% | $0 M | Nov 16, 2026 |
| 11 | Geode Capital Management, LLC | 78,144 | +48,239 (+161.31%) | 1.71% | $0 M | Nov 6, 2026 |
| 12 | Bank Of America Corp /de/ | 75,035 | New | 1.64% | $0 M | Nov 16, 2026 |
| 13 | Jpmorgan Chase & Co | 74,412 | +74,351 (+121886.89%) | 1.63% | $0 M | Nov 12, 2026 |
| 14 | Jane Street Group, LLC | 70,252 | +37,527 (+114.67%) | 1.53% | $0 M | Nov 12, 2026 |
| 15 | Pfizer Inc | 44,357 | +10 (+0.02%) | 0.97% | $0 M | Nov 12, 2026 |
| 16 | Renaissance Technologies LLC | 39,148 | -132,054 (-77.13%) | 0.85% | $0 M | Nov 12, 2026 |
| 17 | BlackRock, Inc. | 36,820 | -528 (-1.41%) | 0.80% | $0 M | Nov 13, 2026 |
| 18 | Millennium Management LLC | 26,526 | -61,586 (-69.90%) | 0.58% | $0 M | Nov 16, 2026 |
| 19 | Vanguard Fiduciary Trust Co | 24,761 | +8,627 (+53.47%) | 0.54% | $0 M | Nov 13, 2026 |
| 20 | Morgan Stanley | 22,932 | +22,866 (+34645.45%) | 0.50% | $0 M | Nov 13, 2026 |
| 21 | Cardiff Park Advisors, LLC | 21,833 | 0 (0.00%) | 0.48% | $0 M | Nov 9, 2026 |
| 22 | Prudential Financial Inc | 17,091 | New | 0.37% | $0 M | Nov 16, 2026 |
| 23 | Nomura Asset Management International Inc. | 12,500 | 0 (0.00%) | 0.27% | $0 M | Nov 16, 2026 |
| 24 | Citigroup Inc | 12,284 | New | 0.27% | $0 M | Nov 4, 2026 |
| 25 | HRT Financial LP | 12,020 | -24,430 (-67.02%) | 0.26% | $0 M | Nov 13, 2026 |
Show all 33: investors 26 to 33
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Acadian Asset Management LLC | 10,664 | -8,318 (-43.82%) | 0.23% | $0 M | Nov 9, 2026 |
| 27 | UBS Group AG | 6,028 | +5,434 (+914.81%) | 0.13% | $0 M | Nov 10, 2026 |
| 28 | Barclays PLC | 5,629 | -97 (-1.69%) | 0.12% | $0 M | Nov 6, 2026 |
| 29 | EverSource Wealth Advisors, LLC | 1,114 | New | 0.02% | $0 M | Nov 4, 2026 |
| 30 | SBI Securities Co., Ltd. | 1,000 | +980 (+4900.00%) | 0.02% | $0 M | Oct 22, 2026 |
| 31 | Tower Research Capital LLC (TRC) | 249 | -1,489 (-85.67%) | 0.01% | $0 M | Nov 16, 2026 |
| 32 | BNP Paribas Financial Markets | 32 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 33 | Caitong International Asset Management Co., Ltd | 18 | New | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding NextCure, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC | 788,700 | $11 M | 28.7% | 0.12% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC | 409,500 | $6 M | 14.9% | 0.12% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Advisor Health Care FundFidelity Management & Research Company LLC | 278,500 | $4 M | 10.1% | 0.12% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC | 195,200 | $3 M | 7.1% | 0.12% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 123,276 | $0 M | 1.3% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 16,250 | $0 M | 0.17% | <0.01% | +25% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 33,566 | $0 M | 0.34% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 3,997 | $0 M | 0.04% | <0.01% | +40% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 3,634 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Nomura Healthcare FundDelaware Management Company | 12,500 | $0 M | 0.13% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 9,851 | $0 M | 0.10% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 2,047 | $0 M | 0.02% | <0.01% | +175% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 3,000 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 741 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 689 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 59 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 22 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 17 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at NextCure, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +12,333 | $5.100 | $63 K | 750,289 | Form 4 |
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +3,662 | $5.100 | $19 K | 737,956 | Form 4 |
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +1,024 | $5.100 | $5 K | 734,294 | Form 4 |
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +3,553 | $5.095 | $18 K | 733,270 | Form 4 |
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +1,672 | $5.034 | $8 K | 729,717 | Form 4 |
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +5,626 | $4.829 | $27 K | 728,045 | Form 4 |
| filed | Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.Former 10% Owner | Sellindirect | -30,000 | $6.160 | $185 K | 308,636 | Form 4 |
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +3,300 | $4.980 | $16 K | 689,416 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: NextCure, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-12.5 reverse split ; 1-for-12.5 reverse split ; 1-for-8.03 reverse split
Trading halts
- 2026-07-16 14:36 UTC, code LUDP, resumed 14:41 UTC
- 2026-03-02 14:43 UTC, code LUDP, resumed 14:53 UTC
- 2025-07-11 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 514 shares at $6.53
- : 310 shares at $5.72
- : 2,715 shares at $6.88
- : 629 shares at $6.28
- : 12 shares at $6.64
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
NextCure, Inc. scorecard#
Passes 2 of the 14 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.9×Price to book 0.9× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-138.0%Free cash flow is -138.0% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-19.65 vs -23.88Diluted EPS -19.65 in fiscal 2025 against -23.88 the year before (report's currency).
- ✗Net income higher than five years earlier-$56 M-$56 M in fiscal 2025 against -$37 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$56 MNet income -$56 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-111.2%-111.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities4.1×Current ratio 4.14 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 3
- ✗Pays a dividendNoNo dividends in fiscal 2025.
- ✗Dividend per share raised five years in a row0 of 5Dividend per share raised in 0 of the five years to fiscal 2025.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year22.0%Diluted shares up 22.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
NextCure, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | — | — | — | — | 22+253%100% | 6.3—100% | — | |
| Research and development | 45+8.3%— | 41−13.4%— | 48−11.6%— | 54+8.0%— | 50+7.8%— | 47+36.1%208% | 34+72.9%539% | 20—— | |
| General and administrative | 13−19.2%— | 16−20.2%— | 20−9.2%— | 22+5.5%— | 21+20.7%— | 17+77.4%76.2% | 9.6+182%151% | 3.4—— | |
| Operating expenses | 58−3.6%— | 60−11.7%— | 68−10.9%— | 76+7.3%— | 71+11.3%— | 64+45.1%284% | 44+89.0%691% | 23—— | |
| Operating income | −58—— | −60—— | −68—— | −76—— | −71—— | −41—−184% | −37—−591% | −23—— | |
| Interest expense and finance costs | — | — | — | — | — | 0.2−12.4%0.8% | 0.2+736%3.3% | 0.0—— | |
| Other non-operating income (expense) | 1.8−56.7%— | 4.1−16.7%— | 4.9+318%— | 1.2−14.5%— | 1.4−70.2%— | 4.6+23.4%20.7% | 3.7+843%59.0% | 0.4—— | |
| Income tax | 0—— | — | — | — | — | — | — | — | |
| Net income including minority interests | −56—— | −56—— | −63—— | −75—— | −69—— | −37—−164% | −34—−532% | −23—— | |
| Net income attributable to shareholders | −56—— | −56—— | −63—— | −75—— | −69—— | −37—−164% | −34—−532% | −23—— | |
| Earnings per share, basic | -19.65—— | -23.88r-1.99—— | -2.25—— | -2.69—— | -2.51—— | -1.33—— | -2.15—— | -16.64—— | |
| Earnings per share, diluted | -19.65—— | -23.88r-1.99—— | -2.25—— | -2.69—— | -2.51—— | -1.33—— | -2.15—— | -16.64—— | |
| Shares, weighted average (basic) | 2.8+22.0%— | 2.3r28−91.6%— | 28+0.3%— | 28+0.5%— | 28+0.3%— | 28—— | — | — | |
| Shares, weighted average (diluted) | 2.8+22.0%— | 2.3r28−91.6%— | 28+0.3%— | 28+0.5%— | 28+0.3%— | 28+75.4%— | 16+1046%— | 1.4—— | |
| Dividends per share | 0.00—— | 0.00—— | 0.00—— | 0.00—— | 0.00—— | 0.00—— | 0.00—— | — | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 26−6.3%51.8% | 28+112%34.3% | 13−50.9%10.2% | 27+116%14.5% | 12r12−62.4%5.1% | 33−3.9%10.7% | 34−74.8%9.6% | 135—91.6% | |
| Short-term investments | — | — | — | — | — | 251−16.6%81.7% | 301—84.4% | — | |
| Other current assets | 1.9−39.5%3.8% | 3.2−28.0%3.9% | 4.4+8.7%3.5% | 4.1−50.5%2.2% | 8.2r8.2+191%3.4% | 2.8−23.3%0.9% | 3.7+2324%1.0% | 0.2—0.1% | |
| Current assets | 44−39.1%87.2% | 72−36.3%88.8% | 113−31.3%88.0% | 164−28.0%89.0% | 228−20.9%94.0% | 288−15.3%93.9% | 340+150%95.5% | 136—92.0% | |
| Property, plant and equipment | 3.3−40.0%6.5% | 5.5−39.6%6.7% | 9.0−24.1%7.1% | 12−15.0%6.5% | 14−11.5%5.8% | 16+30.8%5.2% | 12+6.0%3.4% | 11—7.7% | |
| Right-of-use (leased) assets | 2.6−19.8%5.2% | 3.3−25.8%4.0% | 4.4−12.3%3.4% | 5.0—2.7% | — | — | — | — | |
| Total assets | 50−37.9%100% | 81−36.8%100% | 128−30.5%100% | 184−24.0%100% | 242−21.0%100% | 307−13.9%100% | 356+141%100% | 148—100% | |
| Accounts payable | 2.0−62.4%4.0% | 5.4+130%6.6% | 2.3−45.4%1.8% | 4.3+120%2.3% | 1.9−50.2%0.8% | 3.9+110%1.3% | 1.9−25.1%0.5% | 2.5—1.7% | |
| Debt due within a year | — | — | — | — | — | 1.70.0%0.5% | 1.7+331%0.5% | 0.4—0.3% | |
| Current liabilities | 11+10.4%21.1% | 9.6+39.1%11.8% | 6.9−24.6%5.4% | 9.1+38.1%5.0% | 6.6−36.0%2.7% | 10−31.4%3.4% | 15+46.1%4.2% | 10—7.0% | |
| Long-term debt | — | — | — | — | — | 1.8−45.8%0.6% | 3.3+4466%0.9% | 0.1—0.0% | |
| Lease liabilities (non-current) | 4.1−19.5%8.3% | 5.2−13.4%6.4% | 5.9−9.9%4.6% | 6.6—3.6% | — | — | — | — | |
| Total liabilities | 15−1.0%30.4% | 15+13.0%19.0% | 14−18.1%10.6% | 17+84.8%9.0% | 9.0−30.4%3.7% | 13−62.7%4.2% | 35+7.2%9.7% | 32—21.9% | |
| Retained earnings | −436—−869% | −380—−470% | −324—−253% | −262—−142% | −187—−77.2% | −118—−38.4% | −81—−22.8% | −47—−32.0% | |
| Shareholders' equity | 35−46.6%69.6% | 65−42.8%81.0% | 114−31.7%89.4% | 168−28.2%91.0% | 233−20.5%96.3% | 294−8.6%95.8% | 321—90.3% | −47—−31.8% | |
| Total liabilities and equity | 50−37.9%100% | 81−36.8%100% | 128−30.5%100% | 184−24.0%100% | 242−21.0%100% | 307−13.9%100% | 356+141%100% | 148—100% | |
| Shares outstanding | 3.5+50.2%— | 2.3r28−91.6%— | 28+0.5%— | 28+0.3%— | 28+0.4%— | 28+0.3%— | 27+1900%— | 1.4—— | |
| Cash-flow statement | |||||||||
| Depreciation and amortization | 2.2−24.1%— | 2.9−21.6%— | 3.7−9.8%— | 4.1−4.7%— | 4.3+26.5%— | 3.4r3.4+26.5%15.2% | 2.7+60.3%42.4% | 1.7—— | |
| Share-based compensation | 3.0−52.9%— | 6.3−22.6%— | 8.2−13.9%— | 9.5−7.6%— | 10+30.0%— | 7.9+319%35.4% | 1.9+617%29.7% | 0.3—— | |
| Cash from operating activities | −50—— | −41—— | −53—— | −54—— | −57r−57—— | −45—−201% | −36−546%−561% | 8.0—— | |
| Capital expenditure | — | −0.5—— | −0.8—— | −2.1—— | −2.4—— | −7.1—−31.9% | −3.4—−53.1% | −3.1—— | |
| Cash from investing activities | 26−53.8%— | 55+40.8%— | 39−42.2%— | 68+85.7%— | 37−15.9%— | 44—194% | −304—−4788% | −3.1—— | |
| Debt issued | — | — | — | — | — | — | 4.5—71.5% | — | |
| Debt repaid | — | — | — | — | −3.5—— | −1.5—−6.8% | — | −0.4—— | |
| Shares issued | — | 0.0+680%— | 0.0—— | — | — | 0.1−5.9%0.5% | 0.1+2875%1.9% | 0.0—— | |
| Cash from financing activities | 22+15394%— | 0.1−6.5%— | 0.2−23.0%— | 0.2—— | −3.3—— | −1.4−101%−6.3% | 243+100%3829% | 121—— | |
| Change in cash | −1.7−112%— | 15—— | −14−195%— | 14—— | −24r−24—— | −2.8—−12.7% | −97−176%−1520% | 126—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 26−45.6%— | 4.5−26.1%— | 7.4−69.2%— | 6.8−13.4%— | 6.8*−23.6%— | 6.1−30.0%— | 24+94.0%— | 7.9−30.7%— | 8.9*−24.7%— | 8.8—— | 12—— | 11—— | 12*—— | |
| General and administrative | 13−0.3%— | 4.4+57.6%— | 2.6−19.0%— | 3.3−12.2%— | 3.0*−16.8%— | 2.8−24.6%— | 3.2−21.5%— | 3.7−14.6%— | 3.6*−10.3%— | 3.7—— | 4.1—— | 4.4—— | 4.0*—— | |
| Operating expenses | 42−30.6%— | 6.9−22.6%— | 15−44.7%— | 10−13.1%— | 9.8*−21.7%— | 8.9−28.4%— | 27+65.5%— | 12−36.5%— | 12*−21.1%— | 12—— | 16—— | 18—— | 16*—— | |
| Operating income | −42—— | −6.9—— | −15—— | −10—— | −9.8*—— | −8.9—— | −27—— | −12—— | −12*—— | −12—— | −16—— | −18—— | −16*—— | |
| Other non-operating income (expense) | 0.9−60.7%— | 0.1−77.3%— | 0.2−58.3%— | 0.3−52.2%— | 0.3*−62.3%— | 0.3−66.4%— | 0.5−55.6%— | 0.6−46.0%— | 0.9*−35.6%— | 1.0—— | 1.1—— | 1.2—— | 1.3*—— | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | — | 0—— | 0—— | 0—— | — | |
| Net income including minority interests | −41—— | −6.8*—— | −15*—— | −9.8—— | −9.4*—— | −8.6*—— | −27*—— | −11—— | −12*—— | −12*—— | −15*—— | −17—— | −14*—— | |
| Net income attributable to shareholders | −41—— | −6.8—— | −15—— | −9.8—— | −9.4*—— | −8.6—— | −27—— | −11—— | −12*—— | −12—— | −15—— | −17—— | −14*—— | |
| Earnings per share, basic | — | -1.29—— | -2.80—— | -1.87—— | — | -3.22—— | -11.29—— | -4.70r-0.39—— | — | -4.95r-0.41—— | -6.61r-0.55—— | -0.61—— | — | |
| Earnings per share, diluted | — | -1.29—— | -2.80—— | -1.87—— | — | -3.22—— | -11.29—— | -4.70r-0.39—— | — | -4.95r-0.41—— | -6.61r-0.55—— | -0.61—— | — | |
| Shares, weighted average (basic) | 5.3+98.4%— | 5.3+98.4%— | 5.3+124%— | 5.2+124%— | — | 2.7+14.8%— | 2.4+1.9%— | 2.3r28−91.6%— | — | 2.3r28—— | 2.3r28—— | 28—— | — | |
| Shares, weighted average (diluted) | 5.3+98.4%— | 5.3+98.4%— | 5.3+124%— | 5.2+124%— | — | 2.7+14.8%— | 2.4+1.9%— | 2.3r28−91.6%— | — | 2.3r28—— | 2.3r28—— | 28—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 8.7—90.0% | 8.7+19.2%90.0% | 15+212%67.5% | 15−30.5%39.9% | 26−6.3%51.8% | 7.3−73.6%18.5% | 4.9−76.5%10.3% | 22+18.9%32.5% | 28+112%34.3% | 28—30.7% | 21—20.3% | 18—15.9% | 13—10.2% | |
| Other current assets | 1.0—10.0% | 1.0−72.5%10.0% | 2.2−54.0%9.6% | 2.0−34.2%5.3% | 1.9−39.5%3.8% | 3.5+4.3%8.9% | 4.7+17.1%9.9% | 3.0−53.6%4.5% | 3.2−28.0%3.9% | 3.4—3.7% | 4.0—3.9% | 6.6—5.7% | 4.4—3.5% | |
| Current assets | 9.7—100% | 9.7−70.3%100% | 22−44.4%98.4% | 32−46.1%83.6% | 44−39.1%87.2% | 33−58.5%82.4% | 40−55.8%83.9% | 59−42.6%87.7% | 72−36.3%88.8% | 79—87.1% | 90—88.2% | 103—89.1% | 113—88.0% | |
| Property, plant and equipment | — | — | 0.3−93.2%1.3% | 3.0−37.8%7.9% | 3.3−40.0%6.5% | 3.6−41.0%9.2% | 4.2−37.7%8.7% | 4.8−32.3%7.2% | 5.5−39.6%6.7% | 6.2—6.8% | 6.7—6.5% | 7.1—6.2% | 9.0—7.1% | |
| Right-of-use (leased) assets | 0—0.0% | 0−100%0.0% | — | 2.4−22.8%6.3% | 2.6−19.8%5.2% | 2.8−18.4%7.0% | 2.9−17.2%6.2% | 3.1−14.4%4.6% | 3.3−25.8%4.0% | 3.4—3.8% | 3.6—3.5% | 3.6—3.2% | 4.4—3.4% | |
| Total assets | 9.7—100% | 9.7−75.5%100% | 23−52.6%100% | 38−43.4%100% | 50−37.9%100% | 40−56.2%100% | 48−53.5%100% | 67−41.7%100% | 81−36.8%100% | 90—100% | 103—100% | 115—100% | 128—100% | |
| Accounts payable | 3.0—30.5% | 3.0+23.8%30.5% | 2.6+1.3%11.4% | 3.1+12.2%8.1% | 2.0−62.4%4.0% | 2.4−33.8%6.0% | 2.5−49.9%5.3% | 2.7−39.1%4.1% | 5.4+130%6.6% | 3.6—4.0% | 5.1—4.9% | 4.5—3.9% | 2.3—1.8% | |
| Current liabilities | 4.2—43.3% | 4.2−61.8%43.3% | 6.4−40.5%28.4% | 6.9+20.1%18.1% | 11+10.4%21.1% | 11+26.8%27.8% | 11−0.5%22.6% | 5.7−40.1%8.5% | 9.6+39.1%11.8% | 8.7—9.6% | 11—10.6% | 9.6—8.3% | 6.9—5.4% | |
| Lease liabilities (non-current) | — | — | 3.6−22.8%15.9% | 3.9−21.0%10.2% | 4.1−19.5%8.3% | 4.4−18.1%11.1% | 4.7−16.5%9.8% | 4.9−14.9%7.3% | 5.2−13.4%6.4% | 5.4—6.0% | 5.6—5.4% | 5.8—5.0% | 5.9—4.6% | |
| Total liabilities | 4.2—43.3% | 4.2−73.7%43.3% | 10−34.7%46.3% | 11−0.2%29.7% | 15−1.0%30.4% | 16+8.2%40.3% | 16−6.4%33.6% | 11−30.0%16.8% | 15+13.0%19.0% | 15—16.3% | 17—16.7% | 16—14.0% | 14—10.6% | |
| Retained earnings | −468—−4820% | −468—−4820% | −461—−2037% | −446—−1174% | −436—−869% | −427—−1077% | −418—−876% | −391—−583% | −380—−470% | −369—−408% | −357—−348% | −342—−297% | −324—−253% | |
| Shareholders' equity | 5.5—56.7% | 5.5−76.7%56.7% | 12−59.0%53.7% | 27−52.2%70.3% | 35−46.6%69.6% | 24−68.7%59.7% | 30−65.3%62.2% | 56−43.6%83.2% | 65−42.8%81.0% | 76—83.7% | 85—83.3% | 99—86.0% | 114—89.4% | |
| Total liabilities and equity | 9.7—100% | 9.7−75.5%100% | 23−52.6%100% | 38−43.4%100% | 50−37.9%100% | 40−56.2%100% | 48−53.5%100% | 67−41.7%100% | 81−36.8%100% | 90—100% | 103—100% | 115—100% | 128—100% | |
| Shares outstanding | 4.6—— | 4.6+71.0%— | 4.1+74.1%— | 3.6−87.1%— | 3.5+50.2%— | 2.7−90.4%— | 2.3−91.6%— | 28+0.4%— | 2.3r28−91.6%— | 28—— | 28—— | 28—— | 28—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 1.3−68.6%— | 0.2−67.3%— | 0.3−48.2%— | 0.3−74.8%— | 0.4*−71.4%— | 0.6−60.8%— | 0.6−63.2%— | 1.4−19.5%— | 1.5*−23.4%— | 1.5—— | 1.6—— | 1.7—— | 2.0*—— | |
| Cash from operating activities | −43—— | −12*—— | −9.7*—— | −13—— | −7.6*—— | −6.3*—— | −23*—— | −13—— | −7.0*—— | −11*—— | −9.8*—— | −13—— | −11*—— | |
| Capital expenditure | — | — | — | — | — | — | — | — | — | −0.2*—— | −0.3*—— | −0.0—— | −0.0*—— | |
| Cash from investing activities | 23−14.6%— | 5.5*−36.3%— | 9.8*+160%— | 1.3−81.7%— | 6.0*−13.7%— | 8.7*−52.5%— | 3.8*−69.1%— | 7.1−60.3%— | 7.0*+67.2%— | 18*—— | 12*—— | 18—— | 4.2*—— | |
| Shares issued | — | 0*—— | 0*—— | 1.2—— | — | — | — | — | 0*—— | 0*—— | — | — | — | |
| Cash from financing activities | 22—— | 0.0*—— | 0.0*—— | 1.2—— | 20*+54746%— | 0*—— | — | — | 0.0r0.0*−47.9%— | 0r0.0*—— | 0.1*—— | 0.0—— | 0.1*—— | |
| Change in cash | 1.4—— | −6.5*−369%— | 0.1*—— | −11—— | 19*+71662%— | 2.4*−64.5%— | −17*−780%— | −5.9−212%— | 0.0r0.0*—— | 6.9r6.9*—— | 2.5*—— | 5.3—— | −6.4*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at NextCure, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Michael Richman | $942 K | $1.1 M | $636 K | $84 |
| 2024Michael Richman | $1.5 M | $1.1 M | $876 K | $55 |
| 2023Michael Richman | $1.0 M | $885 K | $690 K | $81 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at NextCure, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Restructuring 1 · Change in control 1 · Directors and officers 4 · Material agreement 4 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| RestructuringChange in controlDirectors and officersMaterial agreement | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at NextCure, Inc.#
2 labor condition applications certified in fiscal 2022 for 2 positions, at a median wage of $98 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| SCIENTIST IIBiochemists and Biophysicists | 2 | $98 K |
Where: Beltsville, MD 2
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2022 | 2 | 2 | $98 K | 2 |
| FY2020 | 1 | 1 | $81 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as NEXTCURE, INC.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How NextCure, Inc. compares in Biotechnology
- Market cap$30 M · higher than 21% of 726
- Revenue growth252.4% · higher than 91% of 438
- Price / book0.9× · lower than 82% of 534
- FCF yield-138.0% · higher than 5% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| NextCure, Inc.🇺🇸 | $30 M | — | — | +252.4% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at NextCure, Inc.? Verify and update this profile — free
Show NextCure, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.